IOL Chemicals & Pharmaceuticals received EDQM CEP approval for Clopidogrel Besilate, strengthening access to regulated European markets. It has huge reserves of Rs.1693 cr. vs equity of Rs.59 cr. and reported PAT of Rs.84.48 cr. in 9MFY26 with 50% interim dividend. The company is expanding API presence with REACH registration, new Minoxidil unit, Paracetamol expansion & Rs.150–200 cr. capex plans. Medium-term growth visibility remains strong with export expansion & margin improvement. Stock may surpass its high of Rs.179.
